Appendix B: Summary of literature on the quality of FIT brands in use by the participating health centers (Hemosure, Insure, and OC-Sensor).( Nielson CM, 2018; de Klerk CM, 2019)(1, 2))

|  |  |  |
| --- | --- | --- |
| FIT BRAND | POSITIVITY | Positive predictive value for advanced neoplasia ( CRC or adenoma)  |
| Hemosure | 21% | 0.39 |
| Insure | 12-23% | 0.53 |
| OC SENSOR | 7-10% | 0.44 |

1. Nielson CM, Petrik AF, Jacob L, Vollmer WM, Keast EM, Schneider JL, et al.Positive predictive values of fecal immunochemical tests used in the STOP CRC pragmatic trial. Cancer Med. 2018;7(9):4781-90.

2. de Klerk CM, Wieten E, van der Steen A, Ramakers CR, Kuipers EJ, Hansen BE, et al.Participation and Ease of Use in Colorectal Cancer Screening: A Comparison of 2 Fecal Immunochemical Tests. Am J Gastroenterol. 2019;114(3):511-8.